Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Alzheimer's Disease and Its Potential Alternative Therapeutics.

Journal of Alzheimer's disease & Parkinsonism

Kisby B, Jarrell JT, Agar ME, Cohen DS, Rosin ER, Cahill CM, Rogers JT, Huang X.
PMID: 31588368
J Alzheimers Dis Parkinsonism. 2019;9(5). doi: 10.4172/2161-0460.1000477. Epub 2019 Sep 13.

Alzheimer's Disease (AD) is a chronic neurodegenerative disease that affects over 5 million individuals in the United States alone. Currently, there are only two kinds of pharmacological interventions available for symptomatic relief of AD; Acetyl Cholinesterase Inhibitors (AChEI) and...

Cite
Kisby B, Jarrell JT, Agar ME, et al. Alzheimer's Disease and Its Potential Alternative Therapeutics. J Alzheimers Dis Parkinsonism. 2019;9(5)doi: 10.4172/2161-0460.1000477.
Kisby, B., Jarrell, J. T., Agar, M. E., Cohen, D. S., Rosin, E. R., Cahill, C. M., Rogers, J. T., & Huang, X. (2019). Alzheimer's Disease and Its Potential Alternative Therapeutics. Journal of Alzheimer's disease & Parkinsonism, 9(5), . https://doi.org/10.4172/2161-0460.1000477
Kisby, Brent, et al. "Alzheimer's Disease and Its Potential Alternative Therapeutics." Journal of Alzheimer's disease & Parkinsonism vol. 9,5 (2019). doi: https://doi.org/10.4172/2161-0460.1000477
Kisby B, Jarrell JT, Agar ME, Cohen DS, Rosin ER, Cahill CM, Rogers JT, Huang X. Alzheimer's Disease and Its Potential Alternative Therapeutics. J Alzheimers Dis Parkinsonism. 2019;9(5). doi: 10.4172/2161-0460.1000477. Epub 2019 Sep 13. PMID: 31588368; PMCID: PMC6777730.
Copy Download .nbib Format: NLM
Designing Socially Assistive Robots for Alzheimer's Disease and Related Dementia Patients and Their Caregivers: Where We are and Where We are Headed.

Healthcare (Basel, Switzerland)

Koutentakis D, Pilozzi A, Huang X.
PMID: 32225117
Healthcare (Basel). 2020 Mar 26;8(2). doi: 10.3390/healthcare8020073.

Over the past few years there has been a large rise in the field of robotics. Robots are being in used in many industries, but there has not been a large surge of robots in the medical field, especially...

Cite
Koutentakis D, Pilozzi A, Huang X. Designing Socially Assistive Robots for Alzheimer's Disease and Related Dementia Patients and Their Caregivers: Where We are and Where We are Headed. Healthcare (Basel). 2020;8(2)doi: 10.3390/healthcare8020073.
Koutentakis, D., Pilozzi, A., & Huang, X. (2020). Designing Socially Assistive Robots for Alzheimer's Disease and Related Dementia Patients and Their Caregivers: Where We are and Where We are Headed. Healthcare (Basel, Switzerland), 8(2), . https://doi.org/10.3390/healthcare8020073
Koutentakis, Dimitrios, et al. "Designing Socially Assistive Robots for Alzheimer's Disease and Related Dementia Patients and Their Caregivers: Where We are and Where We are Headed." Healthcare (Basel, Switzerland) vol. 8,2 (2020). doi: https://doi.org/10.3390/healthcare8020073
Koutentakis D, Pilozzi A, Huang X. Designing Socially Assistive Robots for Alzheimer's Disease and Related Dementia Patients and Their Caregivers: Where We are and Where We are Headed. Healthcare (Basel). 2020 Mar 26;8(2). doi: 10.3390/healthcare8020073. PMID: 32225117; PMCID: PMC7349047.
Copy Download .nbib Format: NLM
An Overview of ICA/BSS-Based Application to Alzheimer's Brain Signal Processing.

Biomedicines

Yang W, Pilozzi A, Huang X.
PMID: 33917280
Biomedicines. 2021 Apr 06;9(4). doi: 10.3390/biomedicines9040386.

Alzheimer's disease (AD) is by far the most common cause of dementia associated with aging. Early and accurate diagnosis of AD and ability to track progression of the disease is increasingly important as potential disease-modifying therapies move through clinical...

Cite
Yang W, Pilozzi A, Huang X. An Overview of ICA/BSS-Based Application to Alzheimer's Brain Signal Processing. Biomedicines. 2021;9(4)doi: 10.3390/biomedicines9040386.
Yang, W., Pilozzi, A., & Huang, X. (2021). An Overview of ICA/BSS-Based Application to Alzheimer's Brain Signal Processing. Biomedicines, 9(4), . https://doi.org/10.3390/biomedicines9040386
Yang, Wenlu, et al. "An Overview of ICA/BSS-Based Application to Alzheimer's Brain Signal Processing." Biomedicines vol. 9,4 (2021). doi: https://doi.org/10.3390/biomedicines9040386
Yang W, Pilozzi A, Huang X. An Overview of ICA/BSS-Based Application to Alzheimer's Brain Signal Processing. Biomedicines. 2021 Apr 06;9(4). doi: 10.3390/biomedicines9040386. PMID: 33917280; PMCID: PMC8067382.
Copy Download .nbib Format: NLM
Overcoming Alzheimer's Disease Stigma by Leveraging Artificial Intelligence and Blockchain Technologies.

Brain sciences

Pilozzi A, Huang X.
PMID: 32210011
Brain Sci. 2020 Mar 23;10(3). doi: 10.3390/brainsci10030183.

Alzheimer's disease (AD) imposes a considerable burden on those diagnosed. Faced with a neurodegenerative decline for which there is no effective cure or prevention method, sufferers of the disease are subject to judgement, both self-imposed and otherwise, that can...

Cite
Pilozzi A, Huang X. Overcoming Alzheimer's Disease Stigma by Leveraging Artificial Intelligence and Blockchain Technologies. Brain Sci. 2020;10(3)doi: 10.3390/brainsci10030183.
Pilozzi, A., & Huang, X. (2020). Overcoming Alzheimer's Disease Stigma by Leveraging Artificial Intelligence and Blockchain Technologies. Brain sciences, 10(3), . https://doi.org/10.3390/brainsci10030183
Pilozzi, Alexander, and Huang, Xudong. "Overcoming Alzheimer's Disease Stigma by Leveraging Artificial Intelligence and Blockchain Technologies." Brain sciences vol. 10,3 (2020). doi: https://doi.org/10.3390/brainsci10030183
Pilozzi A, Huang X. Overcoming Alzheimer's Disease Stigma by Leveraging Artificial Intelligence and Blockchain Technologies. Brain Sci. 2020 Mar 23;10(3). doi: 10.3390/brainsci10030183. PMID: 32210011; PMCID: PMC7139597.
Copy Download .nbib Format: NLM
Classification of MRI and psychological testing data based on support vector machine.

International journal of clinical and experimental medicine

Yang W, Chen X, Cohen DS, Rosin ER, Toga AW, Thompson PM, Huang X.
PMID: 29445429
Int J Clin Exp Med. 2017 Dec;10(12):16004-16026.

Alzheimer's disease (AD) is a progressive, and often fatal, brain disease that causes neurodegeneration, resulting in memory loss as well as other cognitive and behavioral problems. Here, we propose a novel multimodal method combining independent components from MRI measures...

Cite
Yang W, Chen X, Cohen DS, et al. Classification of MRI and psychological testing data based on support vector machine. Int J Clin Exp Med. 2017;10(12):16004-16026
Yang, W., Chen, X., Cohen, D. S., Rosin, E. R., Toga, A. W., Thompson, P. M., & Huang, X. (2017). Classification of MRI and psychological testing data based on support vector machine. International journal of clinical and experimental medicine, 10(12), 16004-16026.
Yang, Wenlu, et al. "Classification of MRI and psychological testing data based on support vector machine." International journal of clinical and experimental medicine vol. 10,12 (2017): 16004-16026.
Yang W, Chen X, Cohen DS, Rosin ER, Toga AW, Thompson PM, Huang X. Classification of MRI and psychological testing data based on support vector machine. Int J Clin Exp Med. 2017 Dec;10(12):16004-16026. PMID: 29445429; PMCID: PMC5808983.
Copy Download .nbib Format: NLM
Current Cognition Tests, Potential Virtual Reality Applications, and Serious Games in Cognitive Assessment and Non-Pharmacological Therapy for Neurocognitive Disorders.

Journal of clinical medicine

Jin R, Pilozzi A, Huang X.
PMID: 33066242
J Clin Med. 2020 Oct 13;9(10). doi: 10.3390/jcm9103287.

As the global population ages, the incidence of major neurocognitive disorders (major NCDs), such as the most common geriatric major NCD, Alzheimer's disease (AD), has grown. Thus, the need for more definitive cognitive assessment or even effective non-pharmacological intervention...

Cite
Jin R, Pilozzi A, Huang X. Current Cognition Tests, Potential Virtual Reality Applications, and Serious Games in Cognitive Assessment and Non-Pharmacological Therapy for Neurocognitive Disorders. J Clin Med. 2020;9(10)doi: 10.3390/jcm9103287.
Jin, R., Pilozzi, A., & Huang, X. (2020). Current Cognition Tests, Potential Virtual Reality Applications, and Serious Games in Cognitive Assessment and Non-Pharmacological Therapy for Neurocognitive Disorders. Journal of clinical medicine, 9(10), . https://doi.org/10.3390/jcm9103287
Jin, Roger, et al. "Current Cognition Tests, Potential Virtual Reality Applications, and Serious Games in Cognitive Assessment and Non-Pharmacological Therapy for Neurocognitive Disorders." Journal of clinical medicine vol. 9,10 (2020). doi: https://doi.org/10.3390/jcm9103287
Jin R, Pilozzi A, Huang X. Current Cognition Tests, Potential Virtual Reality Applications, and Serious Games in Cognitive Assessment and Non-Pharmacological Therapy for Neurocognitive Disorders. J Clin Med. 2020 Oct 13;9(10). doi: 10.3390/jcm9103287. PMID: 33066242; PMCID: PMC7602094.
Copy Download .nbib Format: NLM
Identification and Analysis of Alzheimer's Candidate Genes by an Amplitude Deviation Algorithm.

Journal of Alzheimer's disease & Parkinsonism

Pang C, Yang H, Hu B, Wang S, Chen M, Cohen DS, Chen HS, Jarrell JT, Carpenter KA, Rosin ER, Huang X.
PMID: 31080696
J Alzheimers Dis Parkinsonism. 2019;9(1). doi: 10.4172/2161-0460.1000460. Epub 2019 Feb 02.

BACKGROUND: Alzheimer's disease (AD) is the most common form of senile dementia. However, its pathological mechanisms are not fully understood. In order to comprehend AD pathological mechanisms, researchers employed AD-related DNA microarray data and diverse computational algorithms. More efficient...

Cite
Pang C, Yang H, Hu B, et al. Identification and Analysis of Alzheimer's Candidate Genes by an Amplitude Deviation Algorithm. J Alzheimers Dis Parkinsonism. 2019;9(1)doi: 10.4172/2161-0460.1000460.
Pang, C., Yang, H., Hu, B., Wang, S., Chen, M., Cohen, D. S., Chen, H. S., Jarrell, J. T., Carpenter, K. A., Rosin, E. R., & Huang, X. (2019). Identification and Analysis of Alzheimer's Candidate Genes by an Amplitude Deviation Algorithm. Journal of Alzheimer's disease & Parkinsonism, 9(1), . https://doi.org/10.4172/2161-0460.1000460
Pang, Chaoyang, et al. "Identification and Analysis of Alzheimer's Candidate Genes by an Amplitude Deviation Algorithm." Journal of Alzheimer's disease & Parkinsonism vol. 9,1 (2019). doi: https://doi.org/10.4172/2161-0460.1000460
Pang C, Yang H, Hu B, Wang S, Chen M, Cohen DS, Chen HS, Jarrell JT, Carpenter KA, Rosin ER, Huang X. Identification and Analysis of Alzheimer's Candidate Genes by an Amplitude Deviation Algorithm. J Alzheimers Dis Parkinsonism. 2019;9(1). doi: 10.4172/2161-0460.1000460. Epub 2019 Feb 02. PMID: 31080696; PMCID: PMC6505709.
Copy Download .nbib Format: NLM
Blockchain in Healthcare: A Patient-Centered Model.

Biomedical journal of scientific & technical research

Chen HS, Jarrell JT, Carpenter KA, Cohen DS, Huang X.
PMID: 31565696
Biomed J Sci Tech Res. 2019;20(3):15017-15022. Epub 2019 Aug 08.

A blockchain is a system for storing and sharing information that is secure because of its transparency. Each block in the chain is both its own independent unit containing its own information, and a dependent link in the collective...

Cite
Chen HS, Jarrell JT, Carpenter KA, et al. Blockchain in Healthcare: A Patient-Centered Model. Biomed J Sci Tech Res. 2019;20(3):15017-15022
Chen, H. S., Jarrell, J. T., Carpenter, K. A., Cohen, D. S., & Huang, X. (2019). Blockchain in Healthcare: A Patient-Centered Model. Biomedical journal of scientific & technical research, 20(3), 15017-15022.
Chen, Hannah S, et al. "Blockchain in Healthcare: A Patient-Centered Model." Biomedical journal of scientific & technical research vol. 20,3 (2019): 15017-15022.
Chen HS, Jarrell JT, Carpenter KA, Cohen DS, Huang X. Blockchain in Healthcare: A Patient-Centered Model. Biomed J Sci Tech Res. 2019;20(3):15017-15022. Epub 2019 Aug 08. PMID: 31565696; PMCID: PMC6764776.
Copy Download .nbib Format: NLM
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

EC pharmacology and toxicology

Wang WT, Tailor BA, Cohen DS, Huang X.
PMID: 31565701
EC Pharmacol Toxicol. 2019 Jul;7(7):547-558. Epub 2019 Jun 21.

Alzheimer's disease (AD) characterized by insoluble amyloid-β (Aβ) deposits, neurofibrillary tangles (NFTs), and neuronal demise. The influence of environmental and genetic factors on AD progression remains elusive, however evidence suggests biometal dyshomeostasis elicits neuronal death, neuroinflammation, and accumulated oxidative...

Cite
Wang WT, Tailor BA, Cohen DS, et al. Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics. EC Pharmacol Toxicol. 2019;7(7):547-558
Wang, W. T., Tailor, B. A., Cohen, D. S., & Huang, X. (2019). Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics. EC pharmacology and toxicology, 7(7), 547-558.
Wang, Willam T, et al. "Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics." EC pharmacology and toxicology vol. 7,7 (2019): 547-558.
Wang WT, Tailor BA, Cohen DS, Huang X. Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics. EC Pharmacol Toxicol. 2019 Jul;7(7):547-558. Epub 2019 Jun 21. PMID: 31565701; PMCID: PMC6764777.
Copy Download .nbib Format: NLM
Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease.

Frontiers in neuroscience

Lumsden AL, Rogers JT, Majd S, Newman M, Sutherland GT, Verdile G, Lardelli M.
PMID: 30150923
Front Neurosci. 2018 Aug 13;12:533. doi: 10.3389/fnins.2018.00533. eCollection 2018.

The overwhelming majority of dominant mutations causing early onset familial Alzheimer's disease (EOfAD) occur in only three genes,

Cite
Lumsden AL, Rogers JT, Majd S, et al. Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease. Front Neurosci. 2018;12:533doi: 10.3389/fnins.2018.00533.
Lumsden, A. L., Rogers, J. T., Majd, S., Newman, M., Sutherland, G. T., Verdile, G., & Lardelli, M. (2018). Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease. Frontiers in neuroscience, 12533. https://doi.org/10.3389/fnins.2018.00533
Lumsden, Amanda L, et al. "Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease." Frontiers in neuroscience vol. 12 (2018): 533. doi: https://doi.org/10.3389/fnins.2018.00533
Lumsden AL, Rogers JT, Majd S, Newman M, Sutherland GT, Verdile G, Lardelli M. Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease. Front Neurosci. 2018 Aug 13;12:533. doi: 10.3389/fnins.2018.00533. eCollection 2018. PMID: 30150923; PMCID: PMC6099262.
Copy Download .nbib Format: NLM
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

EC pharmacology and toxicology

Huang X.
PMID: 30215058
EC Pharmacol Toxicol. 2018 Mar;6(3):74-75. Epub 2018 Feb 01.

Recent studies indicate that hyperbaric oxygen therapy (HBOT), a well-established therapy for decompression illness, could be a potential therapy for Alzheimer's disease (AD). However, due to oxygen toxicity i.e., increased oxidative stress implicated in HBOT, the risk and benefit...

Cite
Huang X. Hyperbaric Oxygen Therapy for Alzheimer's Disease. EC Pharmacol Toxicol. 2018;6(3):74-75
Huang, X. (2018). Hyperbaric Oxygen Therapy for Alzheimer's Disease. EC pharmacology and toxicology, 6(3), 74-75.
Huang, Xudong. "Hyperbaric Oxygen Therapy for Alzheimer's Disease." EC pharmacology and toxicology vol. 6,3 (2018): 74-75.
Huang X. Hyperbaric Oxygen Therapy for Alzheimer's Disease. EC Pharmacol Toxicol. 2018 Mar;6(3):74-75. Epub 2018 Feb 01. PMID: 30215058; PMCID: PMC6133268.
Copy Download .nbib Format: NLM
Is it a Prime Time for AI-powered Virtual Drug Screening?.

EC pharmacology and toxicology

Carpenter K, Huang X.
PMID: 30215059
EC Pharmacol Toxicol. 2017;(1):16-17. Epub 2017 Nov 27.

Drug development pipeline inefficiency has called for more novel solutions and cutting-edge technologies. Artificial intelligence (AI)-based methods including different machine- and deep-learning algorithms have been employed for virtual drug screening. With the continuous refinement of algorithms, improvement of computing...

Cite
Carpenter K, Huang X. Is it a Prime Time for AI-powered Virtual Drug Screening?. EC Pharmacol Toxicol. 2017;(1):16-17
Carpenter, K., & Huang, X. (2017). Is it a Prime Time for AI-powered Virtual Drug Screening?. EC pharmacology and toxicology, (1), 16-17.
Carpenter, Kristy, and Huang, Xudong. "Is it a Prime Time for AI-powered Virtual Drug Screening?." EC pharmacology and toxicology vol. ,1 (2017): 16-17.
Carpenter K, Huang X. Is it a Prime Time for AI-powered Virtual Drug Screening?. EC Pharmacol Toxicol. 2017;(1):16-17. Epub 2017 Nov 27. PMID: 30215059; PMCID: PMC6133253.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries